2,903 measles cases, low flu activity: the fall vaccine decisions for U.S. families (2026)

The useful fall question is simple: which vaccine conversation belongs on your calendar now, and which headline still needs more evidence before it changes a routine decision?

Flu is quiet; planning is still timely

The CDC's Week 33 report, published and updated August 28, covers the week ending August 22. Seasonal flu activity remained low. Clinical laboratories found influenza in 200 of 24,572 respiratory specimens, or 0.8%. Public-health laboratories reported 24 positive specimens: 23 influenza A and one influenza B. No H5 specimens were reported, and no new confirmed human novel-influenza infection appeared in that week's report. 1

The other measures were quiet as well. Influenza-like illness accounted for 1.1% of visits nationally. Fifty-three jurisdictions reported minimal activity, two had insufficient data, and none reported moderate, high, or very high activity. FluSurv-NET recorded 30,937 cumulative laboratory-confirmed hospitalizations from October 1, 2025 through August 22, 2026; the Week 33 hospitalization rate was 0.1 per 100,000. 1

Low activity gives families room to plan. CDC guidance says September and October generally work well for most people who need one flu dose, with vaccination ideally completed by the end of October. Some children need two doses at least four weeks apart, so a child who may need a second dose should be checked early. For adults age 65 and older, CDC preferentially recommends Fluzone High-Dose, Flublok, or Fluad when available; another age-appropriate flu vaccine remains an option when those products are unavailable. 2

The current CDC vaccination-trends page still reports 2025-26 data through May 23 for flu vaccination, with updates ending May 29. The page has no 2026-27 flu vaccine-effectiveness estimate. The current surveillance report describes how much flu is circulating; it cannot supply a vaccine-effectiveness percentage. 1 3

Measles numbers have risen, and the death review is unresolved

CDC's measles page was updated August 30 with data through August 27. The page lists 2,903 confirmed U.S. cases in 2026, including 2,887 cases from 47 jurisdictions and 16 cases among international visitors. CDC lists 37 outbreaks, and 94% of cases are associated with an outbreak. The page reports 223 hospitalizations, or 8% of cases. 4

Vaccination records remain the practical place to start. CDC lists 94% of cases as unvaccinated or having an unknown vaccination status, 3% after one MMR dose, and 3% after two doses. The page marks the 2026 death count for review after Pennsylvania reported two measles-associated deaths on August 25; available information has not established whether measles caused or contributed to those deaths. 4

Check each family member's MMR record before school travel or an international trip. CDC says one MMR dose is 93% effective against measles and two doses are 97% effective. A missing record is a reason to ask a clinician or local health department how to document prior vaccination and whether another dose is appropriate for the person's age and circumstances. 4

Pfizer's XFG formula has a narrower U.S. approval

Pfizer and BioNTech announced on August 27 that the U.S. Food and Drug Administration approved the 2026-27 XFG-adapted COMIRNATY formula for adults age 65 and older and for people ages 5 through 64 who have at least one underlying condition that raises their risk of severe COVID-19. Pfizer said shipping began immediately and that pharmacies, hospitals, and clinics should receive doses in the following days. Local availability still needs to be checked with the site offering vaccination. 5

The approval answers an eligibility question for two groups. It does not create a universal appointment instruction for every person age 5 and older. Pfizer also reported strong immune responses against XFG and other contemporary lineages in its submission; that company-reported result is evidence about the filing, while CDC guidance determines how U.S. families should use the product. 5

People considering an mRNA COVID vaccine should share prior vaccine dates, infection history, allergies, and health conditions with the vaccinating clinician. Pfizer's release lists severe allergic reaction precautions and notes that myocarditis and pericarditis have occurred after mRNA COVID vaccination, most often in males ages 12 through 24. A clinician can place those details alongside the person's current risk and prior doses. 5

What this week's immune-system papers add

Systems vaccinology

The review Systems vaccinology and the architecture of human immunity appeared online August 26, 2026, in Nature. Bali Pulendran describes how researchers combine measurements from many layers of biology with computational analysis to find patterns linked to immune responses and to guide future vaccine design. The article is a review of the field rather than a new vaccine trial or a new household dosing study. 6

For families, the useful boundary is timing. A method that helps researchers predict or understand an immune response may support later vaccine development. The review does not establish a current U.S. product choice, a flu-vaccine effectiveness number, or a reason to delay an available vaccination. 6

Why vaccine reactions vary

A study published online August 27, 2026, in Science Translational Medicine examined immune responses around a second mRNA COVID dose and used mechanistic mouse experiments. The researchers linked stronger interferon and inflammatory responses in monocytes with more systemic symptoms and stronger antigen-specific adaptive responses. The abstract returned for the study did not state a participant count, so this article leaves the sample size open rather than filling it in. 7

The finding gives a biological explanation for why one person may feel more fatigue, fever, or aches than another after an mRNA dose. The study does not change vaccine eligibility, routine safety instructions, or the timing guidance above. A person with a concerning reaction should use the advice from the vaccinating clinician and the product information. 7

The fall checklist

Check records this week. Look for each child's MMR doses, flu history, COVID dose dates, allergies, and conditions that raise the risk of severe COVID-19.
Plan flu vaccination for September or October. Ask whether a child needs two doses and whether an age-appropriate vaccine for an adult age 65 or older is available.
Ask about the XFG formula only within its approved groups. Adults age 65 and older and people ages 5 through 64 with at least one qualifying underlying condition are the groups named in Pfizer's FDA approval announcement.
Check local supply before traveling to a pharmacy or clinic. Pfizer described near-term distribution, while each site determines its own appointment and inventory status.
Bring the unresolved questions to a clinician. Ask how prior doses, infections, allergies, age, pregnancy, and health conditions affect the timing that fits one person's record.

This article provides general health information for U.S. families. A clinician, pharmacist, or local health department can apply the current recommendations to an individual record.